BK0713 Sugar Substitute (sweetener)
- 1676.799
- +12.667+0.76%
Zhongtai Securities: Maintaining Sun Paper's (002078.SZ) “Buy” Rating, Strong 24Q1 Performance
The Zhitong Finance App learned that Zhongtai Securities released a research report saying that Sun Paper (002078.SZ)'s integrated advantages of forest pulp and paper are gradually being highlighted,...
COFCO, a Henricksen Company, Opens New Experience Center and Rebrands to Henricksen
WASHINGTON, May 1, 2024 /PRNewswire/ -- Henricksen is pleased to announce the opening of their Washington DC Experience Center located on the 5th floor of 1725 I Street and the rebrand of COFCO, a He
Is Luxin Venture Capital Group (SHSE:600783) Using Too Much Debt?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says 'The biggest investment risk is not the volatility of prices, but whether you will
Sun Paper (002078): Beautiful performance and continued to show resource advantages
The company released its 2024 quarterly report: 2024Q1 achieved revenue of 10.185 billion yuan (+3.9% YoY), net profit of 956 million yuan (YoY +69.0%), net profit of 9.52 billion yuan (YoY), net profit not attributable to mother
Sun Paper (002078): Performance exceeds expectations, profit resilience is highlighted
Guide to this report: Empowered by the deep layout of upstream resources, the upward trend in profit gradually became clear, and management and governance advantages were further established. Key investment points: Raise the target price to 19.9 yuan and maintain the “gain” rating. The 24Q1 company's performance exceeded expectations.
Jinhe Industrial (002597): The price of sweeteners may have bottomed out, and the price of maltol is gradually rising
1Q24 results are in line with market expectations, Jinhe Industrial announced 1Q24 results: revenue of 1,213 billion yuan, down 12.3% year on year, down 0.4% month on month; net profit to mother of 129 million yuan, corresponding to earnings per share of 0.23 million yuan
Jinhe Industrial (002597) 2024 Quarterly Report Review: Profits may have bottomed out, and improving demand is expected to drive economic recovery
Matters: Jinhe Industrial released its report for the first quarter of 2024, achieving revenue of 1,213 billion yuan, -12.30%/+0.36%; achieving net profit to mother of 129 million yuan, or -47.36 million yuan
Express News | Blue Biotech: Currently, the company's stock price has increased significantly, so investors are invited to pay attention to secondary market trading risks
Jinhe Industrial (002597): Prices of sucralose and acesulfame have fallen to the bottom of history, 1Q24 export demand has recovered strongly, and maltol has begun to raise prices
Investment highlights: The company released its 2024 quarterly report, and the performance was in line with expectations. In 1Q24, the company achieved operating income of 1,213 billion yuan (yoy -12.30%, QoQ -0.36%), and net profit to mother was 1
Jiahe Foods (605300.SH): A total cost of 48.06 million yuan to buy back 0.9% of the shares
Gelonghui, April 30丨Jiahe Foods (605300.SH) announced that as of April 30, 2024, the company had repurchased a total of 3,586,098 shares of the company through centralized bidding transactions, accounting for 0.90% of the company's total share capital. The highest repurchase price was 13.50 yuan/share, the lowest price was 12.83 yuan/share, and the total capital paid was RMB 48,060,244.130 (excluding transaction fees such as stamp duty and transaction fees).
Blue Bio (603739): 24Q1 enzyme preparation has impressive growth rate and multiple ways to create a big animal health system
Core view In 2023, the company achieved revenue of 1,199 billion yuan, a year-on-year increase of 3.07%, net profit to mother of 81 million yuan, an increase of 15.56% over the previous year, and plans to distribute a cash dividend of 1.00 per 10 shares to all shareholders
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
The synthetic biology concept strengthened in the afternoon, with Channing Biotech, Shengda Biotech, Blue Bio, and Yiduoli rising and stopping, while Lukang Pharmaceutical, Hanyu Pharmaceutical, and Meihua Biotech followed suit.
Sanyuan Biotech (301206): Performance is in line with market expectations, 1Q24 erythritol sales picked up
The 2023 and 1Q24 results are in line with market expectations Sanyuan Biotech announced 2023 results: achieved revenue of 500 million yuan, a year-on-year decrease of 25.99%; net profit to mother was 59 million yuan, corresponding to earnings per share of 0.2 billion yuan
Sun Paper (002078): Leading the way is steady, 2Q24 is expected to grow steadily
The 1Q24 results are in line with our and market expectations. The company announced 1Q24 results: operating income of 10.2 billion yuan, +3.87% year over year; net profit to mother of 956 million yuan, +69% year over year, in line with our and market expectations. Reviews:
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The food processing sector fluctuated and boosted. Jiabiyou surged 13%, Qiaqia Foods rose more than 6%, and Bowling Bao, Sweet Foods, Jinzai Foods, and Hairong Technology followed suit.
The A-share synthetic biology concept continues to be strong, and Chuan Ning Biotech surged 15%
Glonghui, April 30 | Twining Biotech surged 15%. Previously, Blue Biotech broke out of the 3-row market, with Boen Group, Langkun Environmental, Fuxiang Pharmaceutical, and Jiabiyou leading gains. According to the news, recently, the Shenzhen Synthetic Biology Industry Private Equity Investment Fund Partnership (Limited Partnership) was established. The executive partner is Shenzhen Venture Capital Red Earth Private Equity Investment Fund Management (Shenzhen) Co., Ltd., with an investment amount of 1.5 billion yuan. Earlier, Tan Tianwei, an Academician of the Chinese Academy of Engineering, said that currently, under the leadership of the Development and Reform Commission, the Ministry of Industry and Information Technology, the Ministry of Science and Technology and other national ministries and departments are jointly developing a national action plan for biotechnology and biomanufacturing, which is expected to be introduced in the near future
Blue Biology (603739): Performance growth is in line with expectations and continues to improve the animal health system
Incidents. On April 26, 2024, the company released its 2023 annual report and 2024 quarterly report. In 2023, the company achieved revenue of 1,199 billion yuan, an increase of 3.07% over the previous year; achieved net profit to mother
Luxin Venture Capital (600783.SH) announced first-quarter results with a net loss of 152 million yuan
Lu Xin Venture Capital (600783.SH) released its report for the first quarter of 2024. During the reporting period, it achieved revenue of 16.6599 million yuan, an increase of 9.86% over the previous year. Net loss attributable to shareholders of listed companies was 152 million yuan. Net loss attributable to shareholders of listed companies after deducting non-recurring profit and loss of $153 million.
Jinhe Industrial (002597) Company Comment: Performance is in line with expectations, and subsequent price improvements are expected
On April 29, the company released its 2024 quarterly report. The company achieved revenue of 1,213 billion yuan in the first quarter of 2024, -12.30% year-on-year; net profit to mother was 129 million yuan, or -47.37% year-on-year
Sun Paper (002078): First-quarter results slightly exceeded expectations, profit continued to improve month-on-month
Incident: The company announced its 2024 quarterly report. In the first quarter of 2024, the company achieved revenue of 10.185 billion yuan, an increase of 3.87% year-on-year and a decrease of 1.52% month-on-month; net profit of 956 million yuan was achieved during the same period, with the same period